

Pila Pharma publishes annual report after an eventful 2025

PILA PHARMA has today published its annual report for 2025, which included several interesting elements following an eventful year

PILA PHARMA is a clinical-stage biotech company aiming to develop its lead candidate, the TRPV1 inhibitor "XEN-Do501", as a new first-in-class oral drug for the treatment of obesity, diabetes, other related conditions, and a rare painful disease.

Highlights from the 2025 report

As PILA PHARMA still has no products on the market, the company's revenue opportunities are limited. However, in 2025 PILA PHARMA completed a significantly oversubscribed share issue of nearly 300%, securing financial resources for further development. The company's total cash position at year-end amounted to SEK 19.3 million, compared to SEK 6.4 million at the end of 2024.

As the company has no products on the market, the financial figures are of secondary importance, as the main potential lies in the development of new drug candidates. Nevertheless, we provide a brief review, as several points are considered relevant.

Lower cost level compared to the previous year

In 2025, PILA PHARMA reported an EBIT result of SEK -7.9 million, compared with SEK -8.1 million the year before. The company has thus achieved a lower cash burn while maintaining a higher level of activity. The company has previously highlighted its cost-efficient operating model as an advantage in a challenging stock market environment. No financial guidance for 2026 has been provided in the report, which is common for biotech companies at this stage without revenues.

Cash position above expectations

Despite not being profitable, PILA PHARMA has significantly more cash on its balance sheet than a year ago, primarily due to the successful capital raise. At year-end, the company held total cash of SEK 19.3 million, placing PILA PHARMA in a strong position in a market where drug development is highly capital-intensive. PILA PHARMA is currently in a warrant exercise period and may therefore receive additional capital in the near term, with results expected to be announced around February 16.

Statement from CEO Gustav H. Gram:

Overall, I take many positive moments with me from 2025. We have gained hundreds of new shareholders, and we have succeeded in getting the 'train' (development, ed.) moving and continuing the build-up toward the next level for our organization. The preclinical studies were initiated and completed in accordance with the protocol, but as communicated at the end of January, they have initially proven to be inconclusive.

Nevertheless, we continue toward further clinical trials within obesity, diabetes, and

erythromelalgia, and I would therefore like to thank all PILA PHARMA shareholders for an eventful year with strong support. We look ahead to 2026, where we will move forward into new clinical studies and work to create continued meaningful value for PILA PHARMA – and ultimately for patients.

Contacts

Email: markus@vaekstaktier.dk

Telephone: +45 50 42 99 18

About Us

Disclaimer: Vækstaktier has a paid IR-partnership with the company mentioned. The content is for informational purposes and is a redistribution of the company's own communications.

Website: vaekstaktier.dk